Trial Profile
Efficacy of Ranolazine in LQT3 Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Long QT syndrome
- Focus Therapeutic Use
- 31 Dec 2018 Status changed from recruiting to completed.
- 06 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 06 Dec 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2018.